Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(CML-CP) : A Multicenter, Open-lable, Real World Study

Next Previous
X
Search
Trial Profile

Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia(CML-CP) : A Multicenter, Open-lable, Real World Study

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flumbatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Results (n=446)of real-world effectiveness and safety of flumatinib and nilotinib in patients with newly diagnosed CML-CP, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 01 Nov 2023 Planned number of patients changed from 420 to 491.
    • 11 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top